Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.79
- Piotroski Score 3.00
- Grade Neutral
- Symbol (BNGO)
- Company Bionano Genomics, Inc.
- Price $0.21
- Changes Percentage (1.29%)
- Change -$0
- Day Low $0.20
- Day High $0.22
- Year High $2.27
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/03/2025
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $175.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.18
- Trailing P/E Ratio -0.14
- Forward P/E Ratio -0.14
- P/E Growth -0.14
- Net Income $-232,493,000
Income Statement
Quarterly
Annual
Latest News of BNGO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bionano Genomics (BNGO) Q2 2024 Earnings Call Transcript
Welcome to Bionano's Q2 financial results call. CEO Erik Holmlin and CFO Gulsen Kama lead the discussion. Revenue is $7.8 million, impacted by discontinued clinical services. The focus is on cost savi...
By Yahoo! Finance | 3 months ago
